blood cell formation because it contained the combination of red vitamin B_{12}, folic acid, vitamin C, liver concentrate and iron.

The articles were alleged also to be misbranded under the provisions of the law applicable to foods, as reported in notices of judgment on foods.

DISPOSITION: 6–8–61. The Rexall Drug & Chemical Co., claimant, having consented to the entry of a decree which declared the articles to be misbranded under 403(j) as alleged in the libel, and the court having found the articles to be misbranded under 403(j) without an adjudication of the other charges of misbranding, judgment of condemnation was entered and the articles were released under bond for relabeling.

6885. Rexall Bislumina Acid Guard tablets. (F.D.C. No. 45523. S. Nos. 26–379/80 R, 27–161 R, 27–169 R.)

QUANTITY: 124 cases, each containing a number of ctns., containing 1 50-tablet btl. and 1 6-tablet vial each, at Los Angeles and Vernon, Calif.

SHIPPED: Between 10–14–60 and 3–20–61, from St. Louis, Mo., by Rexall Drug Co.

LABEL IN PART: (Cases, ctns., btls., and insert label in vials) "Rexall Bislumina Acid Guard for relief from gastric hyperacidity contains bismuth aluminate * * * Rexall Drug Company * * * Los Angeles–St. Louis–Toronto * * * Each tablet contains: Magnesium Carbonate 400 mg; Calcium Carbonate (Chalk) 200 mg; Bismuth Aluminate 150 mg; Cortext Frangula (Buckthorn Bark) 25 mg; Calamus Root 25 mg; Carboxymethylcellulose Sodium, Peppermint Oil."

ACCOMPANYING LABELING: Leaflets entitled "Rexall Bislumina Acid Guard An amazing new tablet formulation brings prompt relief to both groups of your patients. For Physician's Information Only."

LIBELED: 3–23–61, S. Dist. Calif.

CHARGE: 502(a)—when shipped, the labeling of the article, namely, the leaflets accompanying the article, contained false and misleading representations that the article was an adequate and effective treatment for peptic ulcers.

DISPOSITION: 5–2–61. Consent—claimed by Rexall Drug & Chemical Co. and leaflets destroyed.

6886. Cobalamed 1000 injection. (F.D.C. No. 46066. S. No. 2–908 R.)

QUANTITY: 300 10-cc.vials, individually ctnd., at Decatur, Ga.

SHIPPED: 6–26–61, from Chicago, Ill., by Medical Chemicals Corp.

LABEL IN PART: (Vial) "Multiple Dose Vial Cobalamed 1000 * * * Injection Cyanocobalamin U.S.P. XVI * * * 106416 Manufactured for Medics Pharmaceutical * * * Atlanta (Decatur), Ga."

ACCOMPANYING LABELING: Insert leaflets entitled "Vitamin B_{12} Description."

LIBELED: 7–5–61, N. Dist. Ga.

CHARGE: 502(a)—when shipped, the labeling of the article contained false and misleading representations that the article was adequate and effective as a treatment for trigeminal neuralgia; toxic, diabetic, alcoholic, and nutritional neuritic disorders; bursitis; acute and chronic liver disease; viral hepatitis; dermatoses such as seborrheic dermatitis, psoriasis, lupus erythematosus, and topical dermatitis.

DISPOSITION: 11–1–61. Consent—claimed by Medical Chemicals Corp., and relabeled.